NRT6003 Injection

DRUG3 trials

Sponsors

Chengdu New Radiomedicine Technology Co. LTD., Second Affiliated Hospital of Guangzhou Medical University

Conditions

Hepatocellular CarcinomaUnresectable Hepatocellular Carcinoma

Phase 1

Safety and Efficacy of TareSphere in Patients With Unresectable Hepatocellular Carcinoma

CompletedNCT06310590

Chengdu New Radiomedicine Technology Co. LTD.Unresectable Hepatocellular Carcinoma

Start: 2023-08-08End: 2025-06-10Updated: 2026-02-03

Phase 2

Yttrium-90 Carbon Microsphere Radioembolization in Previously Treated Hepatocellular Carcinoma

Not yet recruitingNCT07657273

Second Affiliated Hospital of Guangzhou Medical UniversityHepatocellular Carcinoma

Start: 2026-06-22End: 2027-12-21Target: 20Updated: 2026-06-18

Phase 3

Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere

Active, not recruitingNCT06900543

Chengdu New Radiomedicine Technology Co. LTD.Unresectable Hepatocellular Carcinoma

Start: 2025-04-15End: 2027-12-01Target: 108Updated: 2026-06-09

Related Papers

Phase I/II, first-in-human study of yttrium-90 carbon microspheres in patients with unresectable hepatocellular carcinoma: Safety and early efficacy profiles.

Journal of Clinical Oncology2026-05-27